

14 July 2017

OBJ TECHNOLOGY FEATURED BY WORLD RENOWNED DERMATOLOGIST


OBJ Limited (ASX: OBJ) is pleased to announce that OBJ's Research and Development Manager Dr Matthew McIldowie, with Scientific Advisory Board Member Dr Heather Benson, authored a chapter of a prominent new skin penetration science publication that will highlight OBJ's advancements in magnetophoresis and skin science technology overall.

The new publication, by Professor Howard Maibach, Professor of Dermatology at the University of California, San Francisco (UCSF) is titled **Percutaneous Penetration Enhancers Physical Methods in Penetration Enhancement**. It was launched in June in the USA by Springer Scientific Publications.

The chapter authored by Dr McIldowie and Dr Benson, titled "Magnetophoresis: Skin Penetration Enhancement by a Magnetic Field", will bring to the attention of the global skin science community the underlying science, benefits and achievements of OBJ's magnetophoresis technologies and highlights OBJ's global dominance of this area of skin penetration science.

"Professor Howard Maibach is considered the godfather of skin penetration science, and there are none held in greater esteem by the global transdermal drug delivery community," said Jeff Edwards, OBJ's Managing Director and technology founder.

"To have our work and efforts featured so prominently in the foremost scientific publication in its field is a great honor and tribute to the scientific prowess of the OBJ team."



Directors

Mr Glyn Denison
Mr Jeffrey Edwards
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
Fax: +61 8 9443 9960
www.obj.com.au
ABN: 72 056 482 636

ABOUT OBJ

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

14 July 2017

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

ABOUT OBJ'S TECHNOLOGIES

OBJ has developed a number of physical enhancement technologies based on the interactions between ingredient molecules and weak atomic forces. These influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

Complex 3-D magnetic fields produced by low cost microarrays or powdered electromagnetic inductors have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of biological and non-biological targets.

OBJ's low cost micro-array film technology that utilise diamagnetic repulsion, induced permeation and energy redirection has already reached international markets to provide OBJ's Partners with a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical, healthcare and consumer products.

For more information:

Matthew Wright
matt@nwrcommunications.com.au
Phone: +61 451 896 420

Directors

Mr Glyn Denison
Mr Jeffrey Edwards
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered Office:

**284 Oxford Street
Leederville
Western Australia 6007**
Tel: +61 8 9443 3011
Fax: +61 8 9443 9960
www.obj.com.au
ABN: 72 056 482 636